Latest News


Filter by tags: Metastasis Clear all tag filters

6 news articles found

Russia’s AI Leipunsky Institute of Physics & Power Engineering (IPPE) together with V/O Izotop JSC (part of Rusatom Healthcare), have optimised the production process for actinium-225 (Ac-225). Targeted therapy using radiopharmaceuticals based on the radioisotope Ac-225 is proving effective in the treatment of inoperable metastatic cancer. IPPE is one of the three producers of Ac-225 in the world and the only one in Russia.

Date: Saturday, 18 March 2023
Original article:

Rosatom has begun construction of a new plant for the production of medical isotope products at the Karpov Scientific Research Institute of Physics & Chemistry in Obninsk, Kaluga region. The plant will produce a wide range of radiopharmaceuticals including those based on iodine-131, samarium-153, and molybdenum-99 isotopes. It will also develop promising active radiopharmaceuticals based on lutetium-177, actinium-225, radium-223 and other isotopes. Once completed, in 2025, it will be the largest such facility in Europe, Rosatom says. It will operate in accordance with international GMP (good manufacturing practice) standards.

Date: Friday, 27 January 2023
Original article:

US-based Shine Medical Technologies announced on 4 Novemberthat its Therapeutics division has made its first commercial sales of lutetium-177 (Lu-177) to multiple customers. There are dozens of clinical trials studying Lu-177’s potential to treat a range of cancers.

Date: Tuesday, 17 November 2020
Original article:

ITM Medical Isotopes GmbH of Germany and Framatome-Kinectrics joint venture Isogen have signed a formal supply arrangement to provide a reliable supply of lutetium-177 (Lu-177) to the world's health-care system using Bruce Power's Candu reactors as a key supply source. The agreement follows a Memorandum of Understanding signed last November.

Date: Saturday, 31 October 2020
Original article:

Three recent announcements will help secure future supplies of vital medical radioisotopes. Westinghouse Electric Company and Nordion (Canada) Inc are to work together on technology to produce cobalt-60 in pressurised water reactors (PWRs); Framatome and Kinectrics have launched a new joint venture to produce lutetium-177 in partnership with Bruce Power; and BWXT Technologies' proprietary technetium-99m generators have passed a testing milestone.

Date: Saturday, 29 February 2020
Original article:

Canadian Prime Minister Justin Trudeau on 1 November announced funding for construction of the Institute for Advanced Medical Isotopes (IAMI) within the campus of the TRIUMF national particle accelerator at the University of British Columbia in Vancouver. TRIUMF is owned and operated as a joint venture by a consortium of universities. With investment from the Government of Canada, the Province of British Columbia, and contributions from TRIUMF, the BC Cancer Foundation and the University of British Columbia, the construction of the IAMI facility is valued at CAD31.8 million ($24.3m). With additional equipment and philanthropic funding, the total value of the project will be more than CAD50 million. Ottawa is providing $10.2 million, the provincial government $12.2 million, TRIUMF $5.4 million, and the BC Cancer Foundation and UBC $2 million each. Trudeau said: “We know that for our country to lead in an ever-evolving economy and create the jobs of tomorrow, we have to invest in our scientists and in the institutions that support them.”

Date: Monday, 05 November 2018
Original article:


No Tags found.